$116 Million is the total value of DAFNA Capital Management LLC's 46 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DSCO | DISCOVERY LABORATORIES INC | $12,252,000 | -4.4% | 5,698,739 | 0.0% | 10.53% | -20.2% | |
| PLX | PROTALIX BIOTHERAPEUTICS INC | $5,397,000 | +17.7% | 1,178,440 | 0.0% | 4.64% | -1.7% | |
| NXTM | NXSTAGE MEDICAL INC | $4,894,000 | +27.4% | 384,154 | 0.0% | 4.21% | +6.4% | |
| BEAT | BIOTELEMETRY INC | $2,176,000 | +27.1% | 215,645 | 0.0% | 1.87% | +6.1% | |
| NUVASIVE INCnote 2.750% 7/0 | $1,194,000 | +9.3% | 1,000,000 | 0.0% | 1.03% | -8.7% | ||
| ELOS | SYNERON MEDICAL LTD | $1,132,000 | +1.2% | 90,947 | 0.0% | 0.97% | -15.5% | |
| UPI | UROPLASTY INC | $1,050,000 | +32.9% | 289,332 | 0.0% | 0.90% | +10.9% | |
| CUTR | CUTERA INC | $992,000 | +9.9% | 88,694 | 0.0% | 0.85% | -8.2% | |
| JNJ | JOHNSON AND JOHNSON | $923,000 | +7.2% | 9,400 | 0.0% | 0.79% | -10.5% | |
| NSPR | INSPIREMD INC | $875,000 | +24.1% | 286,724 | 0.0% | 0.75% | +3.6% | |
| CLVS | CLOVIS ONCOLOGY INC | $873,000 | +15.0% | 12,600 | 0.0% | 0.75% | -4.0% | |
| ADMP | ADAMIS PHARMACEUTICALS CORP | $795,000 | -0.5% | 125,000 | 0.0% | 0.68% | -16.9% | |
| EXAC | EXACTECH INC | $713,000 | -5.2% | 31,636 | 0.0% | 0.61% | -20.8% | |
| RTIX | RTI SURGICAL INC | $682,000 | +15.4% | 167,058 | 0.0% | 0.59% | -3.6% | |
| OCRX | OCERA THERAPEUTICS INC | $667,000 | -18.8% | 63,223 | 0.0% | 0.57% | -32.2% | |
| MASI | MASIMO CORPORATION | $478,000 | -6.6% | 17,500 | 0.0% | 0.41% | -22.0% | |
| CRIS | CURIS INC | $423,000 | 0.0% | 150,000 | 0.0% | 0.36% | -16.3% | |
| CEMI | CHEMBIO DIAGNOSTICS INC | $190,000 | +2.2% | 55,202 | 0.0% | 0.16% | -14.7% | |
| RVP | RETRACTABLE TECHNOLOGIES INC | $76,000 | +22.6% | 20,000 | 0.0% | 0.06% | +1.6% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.